CervoMed Q3 EPS Forecast Lifted by Brookline Capital Markets

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Markets lifted their Q3 2026 earnings per share estimates for shares of CervoMed in a research note issued on Tuesday, August 11th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will earn ($0.73) per share for the quarter, up from their prior estimate of ($1.04). The consensus estimate for CervoMed’s current full-year earnings is ($2.84) per share. Brookline Capital Markets also issued estimates for CervoMed’s Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.97) EPS.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.22. CervoMed had a negative net margin of 672.80% and a negative return on equity of 166.00%.

Other analysts also recently issued research reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 target price on shares of CervoMed in a report on Wednesday, April 22nd. HC Wainwright reissued a “buy” rating on shares of CervoMed in a report on Wednesday. Roth Capital set a $9.00 price objective on shares of CervoMed in a research report on Monday, May 18th. Weiss Ratings cut CervoMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. Finally, Chardan Capital raised CervoMed to a “strong-buy” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.50.

CervoMed Price Performance

Shares of CRVO opened at $3.07 on Thursday. The firm has a market capitalization of $46.42 million, a PE ratio of -0.95 and a beta of -0.63. The company’s 50-day moving average is $3.12 and its 200-day moving average is $3.77. CervoMed has a fifty-two week low of $2.13 and a fifty-two week high of $11.25.

Insider Buying and Selling at CervoMed

In other news, Director Joshua S. Boger purchased 955,414 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $3.14 per share, with a total value of $2,999,999.96. Following the acquisition, the director owned 1,795,865 shares in the company, valued at approximately $5,639,016.10. The trade was a 113.68% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 35.80% of the company’s stock.

Institutional Investors Weigh In On CervoMed

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new stake in shares of CervoMed in the 1st quarter valued at $227,000. Rhumbline Advisers raised its holdings in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after buying an additional 1,526 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of CervoMed during the 2nd quarter worth $76,000. Jane Street Group LLC acquired a new position in shares of CervoMed during the 2nd quarter worth $414,000. Finally, Vanguard Group Inc. lifted its position in shares of CervoMed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after buying an additional 3,445 shares during the last quarter. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.